October 23, 2026 03:43 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tiger Shroff, not Salman Khan, was the main target, probe reveals shocking details | Dammam airport attack: Indian killed, two compatriots injured as Saudi Arabia faces fresh strikes | ‘Among others’: Macron takes swipe at Trump over France unrest, calls foreign leaders’ remarks ‘stupid’ | ‘Specific threat-related inputs’: Delhi Police blocks Diljit Dosanjh’s Delhi concert | ‘Barbaad kare alfaz mere’: Ranbir Kapoor apologises for Dussehra gaffe in Kolkata | Delhi court releases CJP's Saurav Das and Ashutosh Ranka after 7 days in custody | ‘We are seeing what is happening outside our country’: Delhi HC judge’s remark as CJP leaders Saurav Das and Ashutosh Ranka withdraw custody plea | Salman Khan was the original target? Tiger Shroff firing probe reveals shocking twist | ‘UN experts are an oxymoron’: Marco Rubio takes swipe at UN, refuses to comment on India's protests | ‘US ties with no country come at India's expense’: Marco Rubio addresses concerns over Pakistan, China
COVAXIN

Covaxin's efficacy result will help getting WHO's approval : Govt expert body chief

| @indiablooms | Jul 04, 2021, at 02:04 am

New Delhi/IBNS: India-made Covaxin's recently published result on efficacy will help the vaccine in getting World Health Organisation’s (WHO) emergency approval, the chairperson of National Technical Advisory Group on Immunisation in India (NTAGI), Dr NK Arora said on Saturday.

“This will help to get the vaccine WHO emergency use listing,” Arora told news agency ANI.

The NTAGI chairman also said the approval from the UN health body will bring visibility to India since Covaxin is indigenously developed.

Hyderabad-based biotechnology company Bharat Biotech has claimed its anti-COVID-19 vaccine, Covaxin, is 77.8% effective against the deadly virus.

Bharat Biotech made the claim in the phase three clinical trial data of the vaccine.

The company has further claimed Covaxin is 93.4% effective against severe symptomatic COVID-19 cases, 63.6% against asymptomatic COVID-19 cases and 65.2% against the Delta variant.

“Efficacy analysis demonstrates Covaxin to be 77.8% effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic Covid-19,” the manufacturer said in a paper published in open access journal medRxiv.

"We are working closely with the World Health Organisation for inclusion of Covaxin in its Emergency Use Listing. Approval from WHO is not expected to be a long drawn process as the cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past," Ella tweeted.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.